Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 906673-24-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of topical crisaborole during breastfeeding. Some experts recommend avoiding its use during lactation because of the lack of information.[1,2] In general, drugs applied to the mother’s skin are unlikely to affect the breastfed infant unless it is applied to the nipple or other area where the infant can directly ingest it. Use of crisaborole in nursing mothers is not contraindicated by the product labeling,
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol 2019;33:1644-59. [PubMed: 31231864]
- 2.
- Yaghi M, McMullan P, Truong TM, et al. Safety of dermatologic medications in pregnancy and lactation: An Update - Part II: Lactation. J Am Acad Dermatol 2024. [PubMed: 38280680]
Substance Identification
Substance Name
Crisaborole
CAS Registry Number
906673-24-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.[J Pharmacol Exp Ther. 2016]Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.Dong C, Virtucio C, Zemska O, Baltazar G, Zhou Y, Baia D, Jones-Iatauro S, Sexton H, Martin S, Dee J, et al. J Pharmacol Exp Ther. 2016 Sep; 358(3):413-22. Epub 2016 Jun 27.
- Review Ozanimod.[Drugs and Lactation Database (...]Review Ozanimod.. Drugs and Lactation Database (LactMed®). 2006
- Review Tazarotene.[Drugs and Lactation Database (...]Review Tazarotene.. Drugs and Lactation Database (LactMed®). 2006
- Review Prednicarbate.[Drugs and Lactation Database (...]Review Prednicarbate.. Drugs and Lactation Database (LactMed®). 2006
- Review Amcinonide.[Drugs and Lactation Database (...]Review Amcinonide.. Drugs and Lactation Database (LactMed®). 2006
- Crisaborole - Drugs and Lactation Database (LactMed®)Crisaborole - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...